Extracellular Vesicles Drive Coagulopathy Across Hematologic Cancers
Seminars in Thrombosis and Hemostasis · 24.02.2026
DOI: 10.1055/a-2799-0557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, online erschienen am 24.02.2026. Verfasst von Charlotte Gran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Coagulation Research, Karolinska Institutet, Stockholm, Sweden. Die Arbeit nennt 92 Literaturangaben. Gefördert von: Cancerfonden, Swedish Cancer Society.
Abstract (Originalsprache)
Coagulopathies are common in hematological malignancies and can cause life-threatening bleeding or thrombosis. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, carry cargo that reflects their cellular origin. They frequently express tissue factor (TF) and expose phosphatidylserine (PS), which initiate and amplify coagulation and can also transport fibrinolytic mediators that modulate plasmin generation. Procoagulant EVs are commonly assessed using TF- and PS-dependent functional assays, global hemostasis tests such as overall hemostatic potential, and flow cytometric phenotyping. Clinical and experimental data show elevated EV numbers and activity at diagnosis in several hematological malignancies. In acute leukemias, EV-associated procoagulant activity often declines with treatment yet may remain above control levels, consistent with residual risk. In plasma cell disorders and myeloproliferative neoplasms, platelet-derived and TF/PS-positive EVs are frequently increased and have been linked to enhanced thrombin generation. EVs appear to play key roles across leukemias, multiple myeloma, lymphoid, and myeloproliferative neoplasms. However, considerable methodological heterogeneity, including differences in preanalytical handling, EV isolation, characterization, and activity measurement, limits comparability and clinical translation. Disease-specific mechanistic studies are needed to clarify how EVs modulate hemostasis in different hematologic malignancies. In parallel, standardized protocols and adequately powered clinical studies are required to validate EVs as biomarkers.
Autor:innen und Institutionen
- Department of Molecular Medicine and Surgery, Coagulation Research, Karolinska Institutet, Stockholm, Sweden.
- Clinical Chemistry, Medical Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
- Department of Medicine Huddinge, Gastroenterology and Rheumatology Unit, Karolinska Institute, Stockholm, Sweden.
- Department of Hepatology, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Charlotte Gran
Förderung
- Cancerfonden
- Swedish Cancer Society
Zitieren
APA
Gran, C., Norén, S., & Antovic, J. P. (2026). Extracellular Vesicles Drive Coagulopathy Across Hematologic Cancers. Seminars in Thrombosis and Hemostasis. https://doi.org/10.1055/a-2799-0557
Vancouver
Gran C, Norén S, Antovic JP. Extracellular Vesicles Drive Coagulopathy Across Hematologic Cancers. Seminars in Thrombosis and Hemostasis. 2026. doi:10.1055/a-2799-0557
BibTeX
@article{Gran2026,
author = {Gran, Charlotte and Norén, Sanna and Antovic, Jovan P},
title = {Extracellular Vesicles Drive Coagulopathy Across Hematologic Cancers},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
doi = {10.1055/a-2799-0557}
}
EUVIMED